{"content":"<li class=\"n-box-item date-title\" data-end=\"1503979199\" data-start=\"1503892800\" data-txt=\"Monday, December 23, 2019\">Monday, August 28, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3292247\" data-ts=\"1503964297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292247-marin-softwareminus-4_6-plans-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marin Software -4.6% as it plans reverse split</a></h4><ul>   <li>Marin Software (<a href=\"http://seekingalpha.com/symbol/MRIN\" target=\"_blank\">MRIN</a> <font color='red'>-4.4%</font>), hovering over the $1/share mark for most of the summer, is <font color='red'>down another 4.6%</font> after hours on news that it's <a href=\"https://seekingalpha.com/pr/16925433-marin-software-s-board-directors-approves-reverse-stock-split\" target=\"_blank\">initiating a reverse split</a>.</li>    <li>The board's approved the move, which is subject to stockholder approval.</li>    <li>The company will suggest a ratio of at least 6-to-1 and no greater than 10-to-1, and reduce authorized shares from 500M to a number equal to 500M times twice the reverse split ratio.</li>    <li>It will set the ratio before Oct. 6; it expects to hold a special shareholder meeting on Oct. 5.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292247\" data-linked=\"Marin Software -4.6% as it plans reverse split\" data-tweet=\"$MRIN - Marin Software -4.6% as it plans reverse split https://seekingalpha.com/news/3292247-marin-softwareminus-4_6-plans-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3292247-marin-softwareminus-4_6-plans-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292231\" data-ts=\"1503956194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292231-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/CTLT' title='Catalent'>CTLT</a> <font color='green'>+12.8%</font>. <a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a> <font color='green'>+7.1%</font>. <a href='https://seekingalpha.com/symbol/VIIX' title='VelocityShares VIX Short-Term ETN'>VIIX</a> <font color='green'>+2.8%</font>. <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> <font color='green'>+2.4%</font>. <a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a> <font color='green'>+1.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a> <font color='red'>-22.7%</font>. <a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-7.8%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='red'>-6.5%</font>. <a href='https://seekingalpha.com/symbol/CMRX' title='Chimerix Inc'>CMRX</a> <font color='red'>-5.2%</font>. <a href='https://seekingalpha.com/symbol/PSEC' title='Prospect Capital Corporation'>PSEC</a> <font color='red'>-3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292231\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$CTLT $BW $VIIX - After Hours Gainers / Losers https://seekingalpha.com/news/3292231-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292231-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292226\" data-ts=\"1503954275\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292226-foot-locker-and-nike-whacked-weak-finish-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker and Nike whacked by weak Finish Line guidance</a></h4><ul>     <li>Foot Locker (NYSE:<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a>) is&nbsp;<font color='red'>down 2.80%</font>&nbsp;to $34.70 in AH trading after Finish Line lowers its Q2 guidance dramatically.</li>     <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a>) is&nbsp;<font color='red'>1.36% lower</font>&nbsp;and Dick's Sporting Goods (NYSE:<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a>) is&nbsp;<font color='red'>off 1.11%&nbsp;</font> as the negative sector news is digested.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3292218-finish-line-lowers-guidance-adopts-rights-plan\" target=\"_blank\">Finish Line lowers guidance, adopts rights plan</a> (Aug. 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292226\" data-linked=\"Foot Locker and Nike whacked by weak Finish Line guidance\" data-tweet=\"$FL $FL $NKE - Foot Locker and Nike whacked by weak Finish Line guidance https://seekingalpha.com/news/3292226-foot-locker-and-nike-whacked-weak-finish-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3292226-foot-locker-and-nike-whacked-weak-finish-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292217\" data-ts=\"1503953883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVIV\" target=\"_blank\">NVIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292217-invivo-to-restructure-to-sharpen-focus-on-inspire-study-39-workforce-reduction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InVivo to restructure to sharpen focus on INSPIRE study, 39% workforce reduction</a></h4><ul><li>With the aim of focusing on the INSPIRE study assessing its Neuro-Spinal Scaffold in spinal injury patients, InVivo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a>) will <a href=\"https://seekingalpha.com/pr/16925337-invivo-therapeutics-announces-strategic-corporate-restructuring\" target=\"_blank\">restructure</a>, eliminating 13 jobs (39% of workforce).</li><li>It will suspend its chronic SCI stem cell and gene therapy research programs and halt enrollment in its Canadian cervical Neuro-Spinal Scaffold study until the FDA approves a protocol that allows for U.S. enrollment. The company will evaluate strategic options for the cell and gene therapy programs to enable them to advance with outside funding.</li><li>The initiative should save ~$7.3M in operating expenses next year and lower cash consumption to ~$1.5M per month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292217\" data-linked=\"InVivo to restructure to sharpen focus on INSPIRE study, 39% workforce reduction\" data-tweet=\"$NVIV - InVivo to restructure to sharpen focus on INSPIRE study, 39% workforce reduction https://seekingalpha.com/news/3292217-invivo-to-restructure-to-sharpen-focus-on-inspire-study-39-workforce-reduction?source=tweet\" data-url=\"https://seekingalpha.com/news/3292217-invivo-to-restructure-to-sharpen-focus-on-inspire-study-39-workforce-reduction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292184\" data-ts=\"1503950377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMDA\" target=\"_blank\">KMDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292184-fda-not-on-board-kamadas-inhaled-aat-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA not on board with Kamada&#39;s inhaled AAT; shares down 4%</a></h4><ul><li>Kamada Ltd. (<a href='https://seekingalpha.com/symbol/KMDA' title='Kamada Ltd'>KMDA</a> <font color='red'>-4.4%</font>) says it<a href=\"https://www.sec.gov/Archives/edgar/data/1567529/000117891317002562/zk1720496.htm\" target=\"_blank\"> received a letter</a> from the FDA regarding its proposed protocol for a Phase 3 registration trial for its inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency &#40;AATD&#41;.</li><li>The feedback was not what the company wanted to hear. The agency stated that it \"continues to have concerns and questions\" about the safety and efficacy of inhaled AAT.</li><li>The company intends to continue its dialogue with the regulator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292184\" data-linked=\"FDA not on board with Kamada&#39;s inhaled AAT; shares down 4%\" data-tweet=\"$KMDA - FDA not on board with Kamada&#39;s inhaled AAT; shares down 4% https://seekingalpha.com/news/3292184-fda-not-on-board-kamadas-inhaled-aat-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3292184-fda-not-on-board-kamadas-inhaled-aat-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292182\" data-ts=\"1503949849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292182-hertz-global-bounces-back\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hertz Global bounces back</a></h4><ul> <li>Hertz Global (NYSE:<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a>) <font color='green'>jumps 6.59%</font> on a fresh round of untethered M&amp;A speculation.</li> <li>There's also a <a href=\"http://www.barrons.com/articles/hertz-you-got-it-all-wrong-1503947227\" target=\"_blank\">note</a> out from MKM Partners indicating that Hertz wil navigate its way around any balance sheet issues. \"We believe the company will look to renew/refinance ABS variable funding notes (coming due in 2019), some European fleet seasonal facilities, and its first lien note,\" writes analyst Christopher Agnew.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292182\" data-linked=\"Hertz Global bounces back\" data-tweet=\"$HTZ - Hertz Global bounces back https://seekingalpha.com/news/3292182-hertz-global-bounces-back?source=tweet\" data-url=\"https://seekingalpha.com/news/3292182-hertz-global-bounces-back\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292181\" data-ts=\"1503949553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTLA\" target=\"_blank\">NTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292181-gilead-kite-deal-boosts-gene-editors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead/Kite deal boosts gene editors</a></h4><ul><li>The positive action in biotech has not left out CRISPR/Cas9 gene editing outfits Intellia Therapeutics (<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+19.5%</font>), Editas Medicine (<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+8.3%</font>) and CRISPR Therapeutics (<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a> <font color='green'>+1.6%</font>). All are up on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292181\" data-linked=\"Gilead/Kite deal boosts gene editors\" data-tweet=\"$NTLA $NTLA $EDIT - Gilead/Kite deal boosts gene editors https://seekingalpha.com/news/3292181-gilead-kite-deal-boosts-gene-editors?source=tweet\" data-url=\"https://seekingalpha.com/news/3292181-gilead-kite-deal-boosts-gene-editors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292179\" data-ts=\"1503949463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAA\" target=\"_blank\">PAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292179-analysts-bullish-plains-all-american-cuts-distributions-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts bullish as Plains All American cuts distributions, debt</a></h4><ul>     <li>Plains All American Pipeline (<a href='https://seekingalpha.com/symbol/PAA' title='Plains All American Pipeline, L.P.'>PAA</a> <font color='green'>+1.4%</font>) is higher after analysts issue mostly <a href=\"http://www.barrons.com/articles/wall-street-gets-bullish-as-plains-all-american-cuts-distributions-and-debt-1503936024\" target=\"_blank\">positive reviews</a> of the company's late Friday move to <a href=\"https://seekingalpha.com/news/3291920-plains-american-plans-distribution-cut-1_20-unit\" target=\"_blank\">cut its annual distribution</a> to investors to $1.20/unit from $2.20; general partner Plains GP&nbsp;Holdings (<a href='https://seekingalpha.com/symbol/PAGP' title='Plains GP Holdings, LP'>PAGP</a> <font color='green'>+0.7%</font>) also is slightly higher.</li>     <li>The cut will send PAA's yield to 6% from 10% but it apparently was priced in, and analysts think the distribution can grow in 2019 if the company executes on its debt reduction plans.</li>     <li>Raymond James <a href=\"http://thefly.com/thestreet/realmoney/index.php/PAAid2601583/PAA-Plains-All-American-upgraded-to-Strong-Buy-from-Outperform-at-Raymond-James\" target=\"_blank\">upgrades</a> PAA to Strong Buy from Buy with a $24 price target, seeing \"the newly reduced distribution and faster deleveraging as providing a strong base for both the company to operate from and from which investor expectations can set a reasonable floor.\"</li>     <li>BMO&nbsp;Capital hikes its rating to Outperform with a $25 target, \"dependent on management execution of its fee-based&nbsp;strategy with no need for meaningful Supply &amp; Logistics rebound.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3292179\" data-linked=\"Analysts bullish as Plains All American cuts distributions, debt\" data-tweet=\"$PAA $PAA $PAGP - Analysts bullish as Plains All American cuts distributions, debt https://seekingalpha.com/news/3292179-analysts-bullish-plains-all-american-cuts-distributions-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3292179-analysts-bullish-plains-all-american-cuts-distributions-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292176\" data-ts=\"1503948333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292176-dont-expect-wave-of-acquisitions-from-gilead-kite-deal-guggenheim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Don&#39;t expect wave of acquisitions from Gilead/Kite deal - Guggenheim</a></h4><ul><li>Guggenheim's Tony Butler conjures up some rain on today's Gilead/Kite-stoked biotech parade. He says the $11.9B deal won't necessarily lead to more, especially considering the uncertainty with tax reform and repatriation of overseas cash. The number of global biotech M&amp;A's was on track to be the lowest in four years before today's action.</li><li>Mr. Butler's sober outlook is at odds with other analysts who are much more bullish about the potential for more mergers.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11_9b-cash-kite-16-percent-premarket\" target=\"_blank\">Gilead takes out Kite Pharma for $11.9B in cash; Kite up 16% premarket</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292176\" data-linked=\"Don&#39;t expect wave of acquisitions from Gilead/Kite deal - Guggenheim\" data-tweet=\"Don&#39;t expect wave of acquisitions from Gilead/Kite deal - Guggenheim https://seekingalpha.com/news/3292176-dont-expect-wave-of-acquisitions-from-gilead-kite-deal-guggenheim?source=tweet\" data-url=\"https://seekingalpha.com/news/3292176-dont-expect-wave-of-acquisitions-from-gilead-kite-deal-guggenheim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292175\" data-ts=\"1503948326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292175-chesapeake-range-resources-lead-e-and-p-stocks-lower-harvey-hurts-demand\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chesapeake, Range Resources lead E&amp;P stocks lower as Harvey hurts demand</a></h4><ul>     <li>Oil exploration and production companies including Chesapeake Energy (<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='red'>-3.8%</font>), Range Resources (<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-3.3%</font>) and Anadarko Petroleum (<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a> <font color='red'>-2.9%</font>) are underperforming other energy stocks as lower crude demand after Hurricane Harvey - both from refineries that were forced to close and a lower use of transportation amid flooding - likely will keep crude prices constrained, Bloomberg analyst Vincent Piazza says.</li>     <li>The risk is especially high for companies with exposure to flooding near the Eagle Ford shale, including CHK, Apache (<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a> <font color='red'>-2%</font>), EOG Resources (<a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a> <font color='red'>-1.5%</font>), Sanchez Energy (<a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='red'>-3.8%</font>) and ConocoPhillips (<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips'>COP</a> <font color='red'>-1.4%</font>), Piazza says.</li>     <li>Edward Jones analyst Brian Youngberg says companies such as APA and APC with more exposure to Texan oil basins will feel the lingering impact from Harvey the most, as they will have fewer outlets for their oil.</li>          <li>CHK earlier dropped as much as 5.3% to its lowest intraday reading since May 2016.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292175\" data-linked=\"Chesapeake, Range Resources lead E&amp;P stocks lower as Harvey hurts demand\" data-tweet=\"$CHK $CHK $RRC - Chesapeake, Range Resources lead E&amp;P stocks lower as Harvey hurts demand https://seekingalpha.com/news/3292175-chesapeake-range-resources-lead-e-and-p-stocks-lower-harvey-hurts-demand?source=tweet\" data-url=\"https://seekingalpha.com/news/3292175-chesapeake-range-resources-lead-e-and-p-stocks-lower-harvey-hurts-demand\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292170\" data-ts=\"1503946821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292170-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MXPT' title='MaxPoint Interactive'>MXPT</a> <font color='green'>+149%</font>. <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='green'>+86%</font>. <a href='https://seekingalpha.com/symbol/IXYS' title='IXYS Corporation'>IXYS</a> <font color='green'>+38%</font>. <a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-</font><font color='red'>6%</font>. <a href='https://seekingalpha.com/symbol/SOHU' title='Sohu.com Inc.'>SOHU</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292170\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$MXPT $FSNN $IXYS - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3292170-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292170-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292167\" data-ts=\"1503946396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADTN\" target=\"_blank\">ADTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292167-adtran-establishes-mosaic-alliance-to-push-network-standards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adtran establishes Mosaic alliance to push network standards</a></h4><ul>   <li>Adtran (<a href=\"http://seekingalpha.com/symbol/ADTN\" target=\"_blank\">ADTN</a> <font color='red'>-1.7%</font>) has <a href=\"https://seekingalpha.com/pr/16924537-adtran-establishes-mosaic-open-network-alliance\" target=\"_blank\">established an alliance</a> around its SD-Access solution with a goal of spreading standardization in SDN and NFV.</li>    <li>Built off its Adtran Mosaic offering, the alliance will work to bring together firms working on those solutions.</li>    <li>It will feature two levels, Integration Members (including service partners delivering managed services and system integration) and Collaboration Members. Members have already begun enrolling, the company says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292167\" data-linked=\"Adtran establishes Mosaic alliance to push network standards\" data-tweet=\"$ADTN - Adtran establishes Mosaic alliance to push network standards https://seekingalpha.com/news/3292167-adtran-establishes-mosaic-alliance-to-push-network-standards?source=tweet\" data-url=\"https://seekingalpha.com/news/3292167-adtran-establishes-mosaic-alliance-to-push-network-standards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292166\" data-ts=\"1503946169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXPE\" target=\"_blank\">EXPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292166-expedia-board-member-says-ceo-intends-to-leave-for-uber\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Expedia board member says CEO intends to leave for Uber</a></h4><ul><li>        Expedia (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPE' title='Expedia, Inc.'>EXPE</a>) board member Barry Diller confirms in a reg<a href=\"https://www.cnbc.com/2017/08/28/expedia-8k-dara-khosrowshahi-has-been-asked-to-lead-uber.html\" target=\"_blank\">ulatory filing</a> that CEO Dara Khosrowshahi will likely accept the role of Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber'>UBER</a>) CEO but the deal isn&rsquo;t finalized.</li><li>                  &rdquo;Nothing has been yet finalized, but having extensively discussed this with Dara I believe it is his intention to accept,&rdquo; writes Diller.    </li><li>                  Expedia shares are&nbsp;<font color='red'>down 4.24%.&nbsp;</font>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3291971-recode-uber-chooses-expedias-khosrowshahi-next-ceo\" target=\"_blank\">Recode: Uber chooses Expedia's Khosrowshahi as next CEO</a> (Aug. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292166\" data-linked=\"Expedia board member says CEO intends to leave for Uber\" data-tweet=\"$EXPE $EXPE $UBER - Expedia board member says CEO intends to leave for Uber https://seekingalpha.com/news/3292166-expedia-board-member-says-ceo-intends-to-leave-for-uber?source=tweet\" data-url=\"https://seekingalpha.com/news/3292166-expedia-board-member-says-ceo-intends-to-leave-for-uber\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292163\" data-ts=\"1503945418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSY\" target=\"_blank\">HSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292163-hershey-acquires-shares-from-hershey-trust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hershey acquires shares from Hershey Trust</a></h4><ul>     <li>Hershey (<a href='https://seekingalpha.com/symbol/HSY' title='The Hershey Company'>HSY</a> <font color='red'>-0.8%</font>)&nbsp;purchased 1.5M shares from the Hershey Trust at $106.01 per share, according to a company filing.</li>     <li>The total purchase price of the transaction was $159.015M.</li>     <li><a href=\"https://www.sec.gov/Archives/edgar/data/47111/000004711117000037/a8-k_08282017.htm\" target=\"_blank\">SEC Form 8-K</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292163\" data-linked=\"Hershey acquires shares from Hershey Trust\" data-tweet=\"$HSY - Hershey acquires shares from Hershey Trust https://seekingalpha.com/news/3292163-hershey-acquires-shares-from-hershey-trust?source=tweet\" data-url=\"https://seekingalpha.com/news/3292163-hershey-acquires-shares-from-hershey-trust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292162\" data-ts=\"1503945050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/H\" target=\"_blank\">H</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292162-hyatt-expands-in-shanghai\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hyatt expands in Shanghai</a></h4><ul>     <li>Hyatt Hotels (<a href='https://seekingalpha.com/symbol/H' title='Hyatt Hotels Corporation'>H</a> <font color='red'>-0.4%</font>) opened its seventh Hyatt-branded hotel in       Shanghai with the debut of the 318-room Hyatt Regency Shanghai Global Harbor.</li>     <li>The company says it's committed to growing its       brands in markets where its guests are traveling most.</li>     <li>In <a href=\"https://seekingalpha.com/pr/16905698-hyatt-reports-second-quarter-2017-results\" target=\"_blank\">Q2</a>, Hyatt reported RevPAR grwoth of 7.2% for the segment that includes China.</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/16925211-hyatt-regency-shanghai-global-harbor-opens-east-china\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3292162\" data-linked=\"Hyatt expands in Shanghai\" data-tweet=\"$H - Hyatt expands in Shanghai https://seekingalpha.com/news/3292162-hyatt-expands-in-shanghai?source=tweet\" data-url=\"https://seekingalpha.com/news/3292162-hyatt-expands-in-shanghai\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292161\" data-ts=\"1503944208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRB\" target=\"_blank\">HRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292161-intuit-seen-threat-to-h-and-r-block\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuit seen as a threat to H&amp;R Block</a></h4><ul> <li>BTIG <a href=\"https://www.streetinsider.com/Analyst+Comments/H%26R+Block+%28HRB%29%3A+Intuit+Threat+Comes+Back+Into+Focus+-+BTIG/13241338.html\" target=\"_blank\">doubles down</a> on its bearish call on H&amp;R Block (<a href='https://seekingalpha.com/symbol/HRB' title='H&R Block Inc.'>HRB</a>) with a challenging 2018 seen for the company.</li> <li>Intuit's (<a href='https://seekingalpha.com/symbol/INTU' title='Intuit Inc.'>INTU</a> <font color='green'>+0.6%</font>) plan to focus on building its video chat business is expected to be a threat.</li> <li>BTIG's reiterates a Sell rating on HRB and sets a price target of $19 (9.5X 2018 EPS).</li> <li>Over the last 52 weeks, shares of Intuit have outperformed H&amp;R Block by a 25% return to 22%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292161\" data-linked=\"Intuit seen as a threat to H&amp;R Block\" data-tweet=\"$HRB $HRB $INTU - Intuit seen as a threat to H&amp;R Block https://seekingalpha.com/news/3292161-intuit-seen-threat-to-h-and-r-block?source=tweet\" data-url=\"https://seekingalpha.com/news/3292161-intuit-seen-threat-to-h-and-r-block\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292159\" data-ts=\"1503943950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EHIC\" target=\"_blank\">EHIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292159-on-ehi-car-services-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on eHi Car Services&#39; Q2 results</a></h4><ul>     <li>eHi Car Services (<a href='https://seekingalpha.com/symbol/EHIC' title='eHi Car Services'>EHIC</a> <font color='green'>+2.1%</font>) reports Car rentals revenues rose 28.7% to RMB500.38M in <a href=\"https://seekingalpha.com/pr/16924619-ehi-car-services-announces-second-quarter-2017-results\" target=\"_blank\">Q2</a>.</li>     <li>Car services revenues grew 23.9% to RMB139.37M.</li>     <li>RevPAC increased 3.4% to 154.</li>     <li>Fleet utilization rate<sup>&nbsp;</sup>for car rentals was 72.7%</li>     <li>Gross margin rate improved 90 bps to 29.1%&nbsp;primarily due to a percentage decrease of vehicle-related depreciation in terms of net revenues.</li>     <li>Adjusted EBIT margin rate advanced 300 bps to 15%.</li>     <li>The company expects Q3 revenue to be in the range of RMB780M to RMB800M and for FY2017 to be RMB2.9B.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3292159\" data-linked=\"More on eHi Car Services&#39; Q2 results\" data-tweet=\"$EHIC - More on eHi Car Services&#39; Q2 results https://seekingalpha.com/news/3292159-on-ehi-car-services-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3292159-on-ehi-car-services-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292157\" data-ts=\"1503943235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292157-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/YTEN' title='Yield10 Bioscience, Inc.'>YTEN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/AKG' title='Asanko Gold Inc.'>AKG</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='red'>-8%</font>. EXXI <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TREC' title='Trecora Resources'>TREC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292157\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$YTEN $AXU $USAU - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3292157-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292157-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292148\" data-ts=\"1503940854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDOC\" target=\"_blank\">TDOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292148-bcbs-federal-program-selects-teladoc-for-2018-shares-up-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BCBS federal program selects Teladoc for 2018; shares up 12%</a></h4><ul><li>The Blue Cross and Blue Shield Service Benefit Plan, serving ~5.3M federal government employees, has <a href=\"https://seekingalpha.com/pr/16924738-blue-cross-blue-shield-federal-employee-program-fep-selects-teladoc-provide-telehealth\" target=\"_blank\">selected </a>Teladoc (<a href='https://seekingalpha.com/symbol/TDOC' title='Teladoc Health, Inc.'>TDOC</a> <font color='green'>+12.4%</font>) to provide general medical and behavioral health services for the 2018 benefit year. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292148\" data-linked=\"BCBS federal program selects Teladoc for 2018; shares up 12%\" data-tweet=\"$TDOC - BCBS federal program selects Teladoc for 2018; shares up 12% https://seekingalpha.com/news/3292148-bcbs-federal-program-selects-teladoc-for-2018-shares-up-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3292148-bcbs-federal-program-selects-teladoc-for-2018-shares-up-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292145\" data-ts=\"1503939781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292145-amazon-anxiety-hits-food-industry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon anxiety hits food industry</a></h4><ul> <li>Barclays issues its thoughts on how it see the Whole Foods evolution under Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+0.1%</font>) playing out.</li> <li>The firm expects broad price cuts across key categories, while some areas such as apparel are drastically paired down. Extra store space is seen going to Amazon innovation/help stations and online order pickup/Amazon Lockers.</li><li>Beyond the brick-and-mortar plans from Seattle, pricing strategy is seen as crucial.</li><li>\"If AMZN were to reduce WFM&rsquo;s merchandise margins to KR&rsquo;s (~25%), WFM would generate an operating loss in the $1.2B range annually (excluding any offset from operating expense reductions from automation etc&hellip;),\" calculates Barclays.</li> <li>\"The demise of mediocre conventional retailers will meaningfully accelerate, in our view - as will the demise of other higher priced natural/organic/specialty retailers,\" writes the Barcap team. That last part isn't good news for Vitamin Shoppe (<a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a> <font color='red'>-3.2%</font>), GNC Holdings (<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='red'>-2.5%</font>) and Natural Grocers by Vitamin Cottage (<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color='red'>-2.3%</font>).</li><li>Investors are betting with Barclays on the retail reset today. Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>) is <font color='red'>down 9.64%</font>&nbsp;and is 19% lower over the last three trading sessions, while Apollo-backed Fresh Market bonds have plunged in value. Supervalu (<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a> <font color='red'>-3%</font>) and Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='red'>-0.9%</font>) are also slipping again.</li><li>The food sector is also pricing the impact of Amazon shouldering in to the industry. Post Holdings (<a href='https://seekingalpha.com/symbol/POST' title='Post Holdings, Inc.'>POST</a> <font color='red'>-1.5%</font>), Hershey (<a href='https://seekingalpha.com/symbol/HSY' title='The Hershey Company'>HSY</a> <font color='red'>-1.1%</font>)., Kellogg (<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a> <font color='red'>-2%</font>), Conagra Brands (<a href='https://seekingalpha.com/symbol/CAG' title='ConAgra Brands, Inc.'>CAG</a> <font color='red'>-1.8%</font>), Treehouse Foods (<a href='https://seekingalpha.com/symbol/THS' title='TreeHouse Foods, Inc.'>THS</a> <font color='red'>-1.3%</font>) and Mondelez International (<a href='https://seekingalpha.com/symbol/MDLZ' title='Mondelēz International, Inc.'>MDLZ</a> <font color='red'>-1%</font>) are peeling off value.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292145\" data-linked=\"Amazon anxiety hits food industry\" data-tweet=\"$AMZN $AMZN $VSI - Amazon anxiety hits food industry https://seekingalpha.com/news/3292145-amazon-anxiety-hits-food-industry?source=tweet\" data-url=\"https://seekingalpha.com/news/3292145-amazon-anxiety-hits-food-industry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>130&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292142\" data-ts=\"1503939647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292142-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul>     <li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WSR' title='Whitestone REIT'>WSR</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292142\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$JTPY $RTNB $SUPV - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3292142-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292142-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292140\" data-ts=\"1503939419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292140-fda-conditionally-oks-second-sights-feasibility-study-of-orion-device-shares-ahead-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA conditionally OKs Second Sight&#39;s feasibility study of Orion device; shares ahead 12%</a></h4><ul><li>Thinly traded nano cap Second Sight Medical Products (<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+12%</font>) jumps on more than double normal volume in response to the <a href=\"https://seekingalpha.com/pr/16924693-second-sight-receives-conditional-fda-approval-begin-first-orion-human-clinical-study\" target=\"_blank\">news </a>that the FDA has conditionally approved its clinical trial to evaluate the feasibility of its Orion Cortical Visual Prosthesis System in up to five patients. The approval is conditional because the agency wants the company to conduct additional device testing and address outstanding questions. It has 45 days to respond.</li><li>The company says Orion has the potential to treat almost all forms of blindness. It expects to implant the first patient by year-end.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292140\" data-linked=\"FDA conditionally OKs Second Sight&#39;s feasibility study of Orion device; shares ahead 12%\" data-tweet=\"$EYES - FDA conditionally OKs Second Sight&#39;s feasibility study of Orion device; shares ahead 12% https://seekingalpha.com/news/3292140-fda-conditionally-oks-second-sights-feasibility-study-of-orion-device-shares-ahead-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3292140-fda-conditionally-oks-second-sights-feasibility-study-of-orion-device-shares-ahead-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292139\" data-ts=\"1503939301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YPF\" target=\"_blank\">YPF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292139-ypf-ceo-darre-resigns-six-member-executive-committee-to-run-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YPF CEO Darre resigns; six-member executive committee to run company</a></h4><ul>     <li>CEO&nbsp;Ricardo Darre of Argentine state-owned oil company (<a href='https://seekingalpha.com/symbol/YPF' title='YPF Sociedad Anonima'>YPF</a> <font color='red'>-1.4%</font>) has <a href=\"http://www.reuters.com/article/us-argentina-ypf-ceo-idUSKCN1B81HM\" target=\"_blank\">resigned</a>, and a six-member executive committee will run the company.</li>     <li>YPF does not name a replacement for Darre, who had held the job since July 2016 after previously working for French oil company Total in the U.S.</li>     <li>The executive committee will include Carlos Alfonsi, executive VP for downstream, as executive VP for operations and transformation, and current CFO Daniel Gonzalez as VP of administration and finance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292139\" data-linked=\"YPF CEO Darre resigns; six-member executive committee to run company\" data-tweet=\"$YPF - YPF CEO Darre resigns; six-member executive committee to run company https://seekingalpha.com/news/3292139-ypf-ceo-darre-resigns-six-member-executive-committee-to-run-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3292139-ypf-ceo-darre-resigns-six-member-executive-committee-to-run-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292136\" data-ts=\"1503938423\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292136-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MXPT' title='MaxPoint Interactive'>MXPT</a> <font color='green'>+149%</font>. <a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='green'>+74%</font>. <a href='https://seekingalpha.com/symbol/IXYS' title='IXYS Corporation'>IXYS</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/PERF' title='Perfumania Holdings, Inc'>PERF</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TISI' title='Team, Inc.'>TISI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>&nbsp;<font color='green'>+13%</font></li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OMNT' title='Ominto, Inc.'>OTCPK:OMNT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/HLG' title='Hailiang Education Group Inc.'>HLG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CIE' title='Cobalt International Energy, Inc.'>CIE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292136\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MXPT $FSNN $IXYS - Midday Gainers / Losers https://seekingalpha.com/news/3292136-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3292136-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292134\" data-ts=\"1503937860\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALL\" target=\"_blank\">ALL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292134-harvey-top-10-costly-hurricane-for-insurance-industry-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harvey a top 10 most costly hurricane for insurance industry, analyst says</a></h4><ul>     <li><a href=\"https://www.cnbc.com/2017/08/28/jpmorgan-predicts-harvey-will-be-a-top-10-most-costly-hurricane-for-insurance-industry.html\" target=\"_blank\">Harvey could result in $10B-$20B of industry insured losses</a>, making it one of the top 10 most costly hurricanes to hit the U.S., according to J.P. Morgan analyst Sarah DeWitt.</li>     <li>DeWitt lists Allstate (<a href='https://seekingalpha.com/symbol/ALL' title='Allstate Corporation'>ALL</a> <font color='red'>-1.3%</font>), Arch Capital (<a href='https://seekingalpha.com/symbol/ACGL' title='Arch Capital Group Ltd.'>ACGL</a> <font color='red'>-0.9%</font>), Chubb (<a href='https://seekingalpha.com/symbol/CB' title='Chubb Ltd'>CB</a> <font color='red'>-1.1%</font>), Everest Re (<a href='https://seekingalpha.com/symbol/RE' title='Everest Re Group Ltd.'>RE</a> <font color='red'>-2.9%</font>), Progressive (<a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a> <font color='red'>-2.5%</font>), RenaissanceRe (<a href='https://seekingalpha.com/symbol/RNR' title='RenaissanceRe Holdings Ltd.'>RNR</a> <font color='red'>-1.6%</font>), Travelers (<a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a> <font color='red'>-2.8%</font>), Validus (<a href='https://seekingalpha.com/symbol/VR' title='Validus Holdings, Ltd.'>VR</a> <font color='red'>-2.4%</font>) and XL Group (<a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a> <font color='red'>-2.6%</font>) as the property and casualty insurers with the <a href=\"http://thefly.com/landingPageNews.php?id=2601729&amp;headline=VR;RNR;RE;XL;ACGL;TRV;CB;ALL;PGR-JPMorgan-sees-up-to-B-of-insured-losses-from-Harvey\" target=\"_blank\">most exposure to Texas  hurricanes</a>.</li>     <li>Morgan Stanley's Kai Pan notes that flood losses should dwarf wind losses, impacting commercial players more than personal, particularly Hartford Financial Services (<a href='https://seekingalpha.com/symbol/HIG' title='Hartford Financial Services Group Inc.'>HIG</a> <font color='red'>-1.6%</font>) and TRV.</li>     <li>Deutsche Bank's Joshua Shanker believes commercial carriers such as AIG (<a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> <font color='red'>-0.6%</font>) and CB generally will avoid significant exposure to the event, and personal insurers such as ALL and PGR mostly will be exposed to flooded automobiles; in all  cases, Harvey could best be described as an earnings event and not a balance sheet event.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292134\" data-linked=\"Harvey a top 10 most costly hurricane for insurance industry, analyst says\" data-tweet=\"$ALL $ALL $ACGL - Harvey a top 10 most costly hurricane for insurance industry, analyst says https://seekingalpha.com/news/3292134-harvey-top-10-costly-hurricane-for-insurance-industry-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3292134-harvey-top-10-costly-hurricane-for-insurance-industry-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292133\" data-ts=\"1503937337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292133-fda-accepts-la-jolla-pharmas-marketing-application-for-hypotension-candidate-ljpcminus-501\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts La Jolla Pharma&#39;s marketing application for hypotension candidate LJPC-501, action date February 28, 2018; shares up 10%</a></h4><ul><li>The FDA <a href=\"http://lajollapharmaceutical.com/2017/08/la-jolla-pharmaceutical-company-announces-u-s-fda-acceptance-of-new-drug-application-for-ljpc-501/\" target=\"_blank\">accepts for review</a> La Jolla Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+10.1%</font>) New Drug Application &#40;NDA&#41; seeking approval for LJPC-501 (angiotensin II) for the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy. The agency's action date under Priority Review is February 28, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269008-la-jollas-ljpcminus-501-achieves-primary-endpoint-late-stage-study-patients-life-threatening\" target=\"_blank\">La Jolla's LJPC-501 achieves primary endpoint in late-stage study in patients with life-threatening drop in blood pressure; shares down 10% premarket on disappointing effect on mortality</a> (May 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292133\" data-linked=\"FDA accepts La Jolla Pharma&#39;s marketing application for hypotension candidate LJPC-501, action date February 28, 2018; shares up 10%\" data-tweet=\"$LJPC - FDA accepts La Jolla Pharma&#39;s marketing application for hypotension candidate LJPC-501, action date February 28, 2018; shares up 10% https://seekingalpha.com/news/3292133-fda-accepts-la-jolla-pharmas-marketing-application-for-hypotension-candidate-ljpcminus-501?source=tweet\" data-url=\"https://seekingalpha.com/news/3292133-fda-accepts-la-jolla-pharmas-marketing-application-for-hypotension-candidate-ljpcminus-501\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292130\" data-ts=\"1503936751\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALQA\" target=\"_blank\">ALQA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292130-fda-clears-alliqua-biomedicals-silverseal-wound-dressing-shares-up-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Alliqua BioMedical&#39;s SilverSeal wound dressing; shares up 32%</a></h4><ul><li>Thinly traded nano cap Alliqua BioMedical (<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='green'>+31.9%</font>) jumps on more than an 11x surge in volume on the news that the FDA has granted <a href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171041\" target=\"_blank\">510(k) clearance</a> for its <a href=\"https://alliqua.com/products/silverseal/\" target=\"_blank\">SilverSeal Hydrogel wound dressing</a>.</li><li>SilverSeal, comprised of 1.5% of almost pure silver, promotes wound healing and delivers broad spectrum antimicrobial activity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292130\" data-linked=\"FDA clears Alliqua BioMedical&#39;s SilverSeal wound dressing; shares up 32%\" data-tweet=\"$ALQA $ADYX - FDA clears Alliqua BioMedical&#39;s SilverSeal wound dressing; shares up 32% https://seekingalpha.com/news/3292130-fda-clears-alliqua-biomedicals-silverseal-wound-dressing-shares-up-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3292130-fda-clears-alliqua-biomedicals-silverseal-wound-dressing-shares-up-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292129\" data-ts=\"1503936077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292129-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HOME' title='At Home Group'>HOME</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MBUU' title='Malibu Boats, Inc.'>MBUU</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292129\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$HOME $WKHS $LCII - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3292129-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3292129-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292128\" data-ts=\"1503936072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLO\" target=\"_blank\">VLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292128-texas-refinery-shutdowns-push-company-shares-sharply-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Texas refinery shutdowns push company shares sharply higher</a></h4><ul>     <li>Shares of oil refinery companies are <a href=\"https://www.cnbc.com/2017/08/28/us-stocks-refiners-harvey-economy.html\" target=\"_blank\">rallying</a> after Hurricane Harvey forced Houston-area refiners to <a href=\"https://seekingalpha.com/news/3291970-houston-refineries-including-exxons-baytown-shut-harvey\" target=\"_blank\">shut down</a>: <a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='green'>+0.6%</font>, <a href='https://seekingalpha.com/symbol/ANDV' title='Andeavor'>ANDV</a> <font color='green'>+3.7%</font>, <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='green'>+8.5%</font>, <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+7.7%</font>, <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+3.4%</font>, <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+1.9%</font>, <a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='green'>+7.7%</font>.</li>          <li>Meanwhile, oil and gas producers, drillers, equipment and service companies are all trading lower on weak oil prices.</li>     <li>\"With some of the major refineries closing down in Houston, we're seeing fireworks in gasoline prices, a move which is being reflected in refinery stocks,\" says Peter Cardillo, chief market economist at First  Standard Financial.</li>     <li>\"We're looking at a mini-gasoline spike at the prospect of millions of barrels a day of U.S. refining capacity lost for at least a period of days,\" says Tom Kloza, global head of energy analysis at the Oil Price  Information Service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292128\" data-linked=\"Texas refinery shutdowns push company shares sharply higher\" data-tweet=\"$VLO $VLO $MPC - Texas refinery shutdowns push company shares sharply higher https://seekingalpha.com/news/3292128-texas-refinery-shutdowns-push-company-shares-sharply-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3292128-texas-refinery-shutdowns-push-company-shares-sharply-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292104\" data-ts=\"1503933639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292104-biogens-alzheimers-candidate-aducanumab-shows-long-term-treatment-effect-in-extension-phase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen&#39;s Alzheimer&#39;s candidate aducanumab shows long-term treatment effect in extension phase of early-stage study</a></h4><ul><li>Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+2.5%</font>) is up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16924634-biogen-reports-new-data-phase-1b-study-investigational-alzheimer-s-disease-treatment\" target=\"_blank\">announcement </a>of positive data from the long-term extension of its ongoing Phase 1b clinical trial assessing Alzheimer's disease &#40;AD&#41; candidate aducanumab.</li><li>In patients treated up to 36 months, amyloid plaque, measured by PET imaging, continued to decrease in a dose- and time-dependent manner, with amyloid plaque levels in the 10 mg/kg fixed-dose cohort reaching and remaining at a level regarded as a negative scan.</li><li>Additional data will be submitted for presentation at a future medical conference.</li><li><a href=\"http://www.neurimmune.com/products/alzheimers-disease.html\" target=\"_blank\">Aducanumab&nbsp;</a>is a human recombinant monoclonal antibody derived from a library of B cells collected from healthy elderly subjects with no signs of cognitive impairment. It is being developed under a&nbsp;<a href=\"http://www.neurimmune.com/newsartikel/20112007-biogen-idec-and-neurimmune-therapeutics-announce-alliance-to-develop-treatments-for-alzheimers-disease-.html\" target=\"_blank\">global deal</a>&nbsp;with&nbsp;<a href=\"http://www.neurimmune.com/company/about-neurimmune.html\" target=\"_blank\">Neurimmune</a>&nbsp;inked in November 2007. Two Phase 3 studies are in process.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292104\" data-linked=\"Biogen&#39;s Alzheimer&#39;s candidate aducanumab shows long-term treatment effect in extension phase of early-stage study\" data-tweet=\"$BIIB - Biogen&#39;s Alzheimer&#39;s candidate aducanumab shows long-term treatment effect in extension phase of early-stage study https://seekingalpha.com/news/3292104-biogens-alzheimers-candidate-aducanumab-shows-long-term-treatment-effect-in-extension-phase?source=tweet\" data-url=\"https://seekingalpha.com/news/3292104-biogens-alzheimers-candidate-aducanumab-shows-long-term-treatment-effect-in-extension-phase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292111\" data-ts=\"1503933474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCO\" target=\"_blank\">ARCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292111-citi-upgrade-lifts-arcos-dorados\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi upgrade lifts Arcos Dorados</a></h4><ul> <li>Shares of Arcos Dorados (<a href='https://seekingalpha.com/symbol/ARCO' title='Arcos Dorados'>ARCO</a> <font color='green'>+2.3%</font>) head higher after Citigroup <a href=\"https://twitter.com/usratings/status/902172039309615105\" target=\"_blank\">tags</a> the restaurant stock with a Buy rating.</li> <li>The Citi team has a favorable view on the consumer recovery trends in play across Brazil and Argentina. Arcos' 2017 revenue is forecast by Citi to rise 5%, up from the firm's prior view of 4% growth.</li> <li>Citi's price target of $10.60 reps 20% upside potential on Arcos.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292111\" data-linked=\"Citi upgrade lifts Arcos Dorados\" data-tweet=\"$ARCO - Citi upgrade lifts Arcos Dorados https://seekingalpha.com/news/3292111-citi-upgrade-lifts-arcos-dorados?source=tweet\" data-url=\"https://seekingalpha.com/news/3292111-citi-upgrade-lifts-arcos-dorados\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292081\" data-ts=\"1503932421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292081-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DMTX' title='Dimension Therapeutics'>DMTX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/IMNP' title='Immune Pharmaceuticals Inc.'>OTCQB:IMNP</a> <font color='red'>-5%</font>. APRI <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292081\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$KITE $BLCM $JUNO - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3292081-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3292081-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292101\" data-ts=\"1503932081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSNN\" target=\"_blank\">FSNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292101-fusion-telecom-up-70-on-cloud-combo-birch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fusion Telecom up 70% on cloud combo with Birch</a></h4><ul>   <li>Fusion Telecommunications (NASDAQ:<a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a>) is <font color='green'>up 70%</font> after announcing that it will <a href=\"https://seekingalpha.com/pr/16924694-fusion-announces-definitive-agreement-acquire-birch-communications-cloud-business-services\" target=\"_blank\">buy the cloud and business services unit</a> of Birch Communications in an all-stock deal to create one of North America's biggest cloud service providers.</li>    <li>The combined company will be worth about $950M including debt; Fusion started the day with a market cap of $27.6M. The new firm will have more than 150,000 business customers, 30 data centers, 31,000 fiber route miles and metro fiber assets in 11 major markets.</li>    <li>The combination is also expected to have pro forma annual revenue of $575M, with more than $150M in pro forma annual EBITDA. Net debt is expected to be less than 4x EBITDA.</li>    <li>Privately held Birch will get about 73M common shares of Fusion valued at $3.85/share, a 200% premium compared to Friday. Fusion shareholders will own 25% of the combination while Birch shareholders will own 75%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292101\" data-linked=\"Fusion Telecom up 70% on cloud combo with Birch\" data-tweet=\"$FSNN - Fusion Telecom up 70% on cloud combo with Birch https://seekingalpha.com/news/3292101-fusion-telecom-up-70-on-cloud-combo-birch?source=tweet\" data-url=\"https://seekingalpha.com/news/3292101-fusion-telecom-up-70-on-cloud-combo-birch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292099\" data-ts=\"1503931898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292099-rv-stocks-shoot-higher-amid-texas-flooding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RV stocks shoot higher amid Texas flooding</a></h4><ul> <li>Mark it down as a RV rally as investors bet on an increase in demand due to the massive flooding in Texas.</li> <li>Thor Industries (<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a> <font color='green'>+6.2%</font>), Winnebago Industries (<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a> <font color='green'>+4.9%</font>), Patrick Industries (<a href='https://seekingalpha.com/symbol/PATK' title='Patrick Industries, Inc.'>PATK</a> <font color='green'>+3.4%</font>) and LCI Industries (<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a> <font color='green'>+5.9%</font>) are all higher</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292099\" data-linked=\"RV stocks shoot higher amid Texas flooding\" data-tweet=\"$THO $THO $WGO - RV stocks shoot higher amid Texas flooding https://seekingalpha.com/news/3292099-rv-stocks-shoot-higher-amid-texas-flooding?source=tweet\" data-url=\"https://seekingalpha.com/news/3292099-rv-stocks-shoot-higher-amid-texas-flooding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292097\" data-ts=\"1503931642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMID\" target=\"_blank\">AMID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292097-american-midstream-cut-to-sector-perform-rbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Midstream cut to Sector Perform at RBC</a></h4><ul>     <li>American Midstream Partners (<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a> <font color='red'>-2.1%</font>) is <a href=\"http://thefly.com/thestreet/realmoney/index.php/AMIDid2601621/AMID-American-Midstream-downgraded-on-likely-deals-lack-of-visibility-at-RBC-Capital\" target=\"_blank\">downgraded</a> to Sector Perform from Outperform with a $14 price target, cut from $18, at RBC Capital, as AMID has leaned more heavily on sponsor support than the firm expected to hit 2017 targets.</li><li>With propane being sold, AMID now has ambitious plans to materially grow  EBITDA in 2018 while also alleviating the need for more sponsor support, but RBC believes current assets will not be sufficient and sees more A&amp;D announcements forthcoming.</li><li>RBC praises AMID's experienced management team but says visibility is more limited to hit its targets.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3292097\" data-linked=\"American Midstream cut to Sector Perform at RBC\" data-tweet=\"$AMID - American Midstream cut to Sector Perform at RBC https://seekingalpha.com/news/3292097-american-midstream-cut-to-sector-perform-rbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3292097-american-midstream-cut-to-sector-perform-rbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292095\" data-ts=\"1503931589\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292095-biotechs-up-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs up in early trading</a></h4><ul><li>Led by the Gilead's $11.9B takeover of Kite Pharma, biotechs are leading market in early trading.</li><li>Selected tickers: (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+1.8%</font>)(<a href='https://seekingalpha.com/symbol/XBI' title='SPDR Biotech ETF'>XBI</a> <font color='green'>+2.5%</font>)(<a href='https://seekingalpha.com/symbol/BBH' title='VanEck Vectors Biotech ETF'>BBH</a> <font color='green'>+1%</font>)(<a href='https://seekingalpha.com/symbol/FBT' title='First Trust NYSE Arca Biotechnology Index ETF'>FBT</a> <font color='green'>+2.5%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+28.4%</font>)(<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+15.6%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+1.5%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+2.4%</font>)(<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='green'>+2.1%</font>)(<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+1.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292095\" data-linked=\"Biotechs up in early trading\" data-tweet=\"$GILD $IBB $XBI - Biotechs up in early trading https://seekingalpha.com/news/3292095-biotechs-up-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3292095-biotechs-up-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292094\" data-ts=\"1503931314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292094-coherus-bios-humira-biosimilar-candidate-shows-shows-bioequivalence-in-early-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus Bio&#39;s Humira biosimilar candidate shows shows bioequivalence in early-stage study; shares ahead 3%</a></h4><ul><li>Coherus BioSciences (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+3.2%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16924799-coherus-biosciences-announces-positive-topline-results-clinical-pharmacokinetic\" target=\"_blank\">announcement </a>of positive results from the first of three pharmacokinetic bioequivalence (PK/BE) studies comparing biosimilar candidate CHS-1420 to the reference drug Humira (adalimumab). The study met the criteria for clinical PK/BE on all endpoints.</li><li>Development is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292094\" data-linked=\"Coherus Bio&#39;s Humira biosimilar candidate shows shows bioequivalence in early-stage study; shares ahead 3%\" data-tweet=\"$CHRS - Coherus Bio&#39;s Humira biosimilar candidate shows shows bioequivalence in early-stage study; shares ahead 3% https://seekingalpha.com/news/3292094-coherus-bios-humira-biosimilar-candidate-shows-shows-bioequivalence-in-early-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3292094-coherus-bios-humira-biosimilar-candidate-shows-shows-bioequivalence-in-early-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292090\" data-ts=\"1503930551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292090-fda-oks-abbotts-heartmate-3-lvad-device-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Abbott&#39;s HeartMate 3 LVAD device; shares up 1%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16924914-abbott-introduces-heartmate-3-left-ventricular-assist-system-latest-milestone-therapy\" target=\"_blank\">approves </a>Abbott's (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='green'>+0.6%</font>) Full MagLev HeartMate 3 Left Ventricular Assist System &#40;LVAD&#41; for the management of advanced heart failure patients who need short-term hemodynamic support. The device employs full magnetic levitation to reduce trauma to blood passing through the system and improve blood flow.</li><li>The data supporting the marketing application was generated in a study called MOMENTUM 3 which showed patients using the device experienced an 83% increase in walk distance and a 68% improvement in quality-of-life measures. Users also experienced a survival rate of 86% with freedom from disabling stroke and reoperation to replace the pump at six months.</li><li>The product was CE Mark'd in Europe in October 2015.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292090\" data-linked=\"FDA OKs Abbott&#39;s HeartMate 3 LVAD device; shares up 1%\" data-tweet=\"$ABT - FDA OKs Abbott&#39;s HeartMate 3 LVAD device; shares up 1% https://seekingalpha.com/news/3292090-fda-oks-abbotts-heartmate-3-lvad-device-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3292090-fda-oks-abbotts-heartmate-3-lvad-device-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292088\" data-ts=\"1503929995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFM\" target=\"_blank\">SFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292088-sprouts-farmers-market-falls-again\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprouts Farmers Market falls again</a></h4><ul> <li>Sprouts Farmers Market (NASDAQ:<a href='https://seekingalpha.com/symbol/SFM' title='Sprouts Farmers Market'>SFM</a>) is <font color='red'>down another 6.0%</font> as the grocery stocks continues to get sold off by investors over concerns on Amazon lowering prices at Whole Foods.</li> <li>Late last week, Jefferies came out in defense of the grocery sector, saying it didn't make sense to punish the stocks twice for the same reason.</li> <li>Sprouts sold off in the days after the Amazon-Whole Foods decision was announced on the conclusion that organic food pricing from Seattle would get aggresssive.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291634-grocery-sector-reeling-amazon-hitting-ground-running\" target=\"_blank\">Grocery sector reeling with Amazon hitting the ground running</a> (Aug. 24)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292088\" data-linked=\"Sprouts Farmers Market falls again\" data-tweet=\"$SFM - Sprouts Farmers Market falls again https://seekingalpha.com/news/3292088-sprouts-farmers-market-falls-again?source=tweet\" data-url=\"https://seekingalpha.com/news/3292088-sprouts-farmers-market-falls-again\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292087\" data-ts=\"1503929565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292087-fda-oks-tandem-diabetes-cares-new-t-slim-x2-insulin-pump-shares-up-63\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Tandem Diabetes Care&#39;s new t:slim X2 insulin pump; shares up 63%</a></h4><ul><li>Nano cap Tandem Diabetes Care (<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color='green'>+62.8%</font>) jumps on the <a href=\"https://seekingalpha.com/pr/16924777-tandem-diabetes-care-announces-fda-approval-launch-t-slim-x2-insulin-pump-dexcom-g5-mobile\" target=\"_blank\">news </a>that the FDA has approved its t:slim X2 Insulin Pump that is integrated with DexCom's (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='red'>-0.4%</font>) G5 Mobile continuous glucose monitor. The company says it is the first sensor-augmented insulin pump approved that allows users to make treatment decisions without a finger-prick blood sample.</li><li>Commercial launch is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292087\" data-linked=\"FDA OKs Tandem Diabetes Care&#39;s new t:slim X2 insulin pump; shares up 63%\" data-tweet=\"$TNDM $TNDM $DXCM - FDA OKs Tandem Diabetes Care&#39;s new t:slim X2 insulin pump; shares up 63% https://seekingalpha.com/news/3292087-fda-oks-tandem-diabetes-cares-new-t-slim-x2-insulin-pump-shares-up-63?source=tweet\" data-url=\"https://seekingalpha.com/news/3292087-fda-oks-tandem-diabetes-cares-new-t-slim-x2-insulin-pump-shares-up-63\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292085\" data-ts=\"1503929234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXRH\" target=\"_blank\">TXRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292085-restaurant-names-hit-hurricane-related-traffic-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restaurant names hit by hurricane-related traffic concerns</a></h4><ul> <li>A number of restaurants stocks are lower on the day as the impact of Hurricane Harvey is factored in for chains with high mix of outlets in and around Houston.</li> <li>Notable decliners include Texas Roadhouse (<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a> <font color='red'>-2%</font>), Sonic (<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='red'>-2.2%</font>), Ruby Tuesday (<a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='red'>-2%</font>), El Pollo Loco (<a href='https://seekingalpha.com/symbol/LOCO' title='El Pollo Loco Holdings'>LOCO</a> <font color='red'>-1.5%</font>), Del Taco (<a href='https://seekingalpha.com/symbol/TACO' title='Del Taco Restaurants, Inc.'>TACO</a> <font color='red'>-1.3%</font>), Jack In The Box (<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a> <font color='red'>-2.2%</font>) and Dave &amp; Buster's Entertainment (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-4.1%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292085\" data-linked=\"Restaurant names hit by hurricane-related traffic concerns\" data-tweet=\"$TXRH $TXRH $SONC - Restaurant names hit by hurricane-related traffic concerns https://seekingalpha.com/news/3292085-restaurant-names-hit-hurricane-related-traffic-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/3292085-restaurant-names-hit-hurricane-related-traffic-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292077\" data-ts=\"1503927911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GCO\" target=\"_blank\">GCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292077-susquehanna-sours-on-genesco\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna sours on Genesco</a></h4><ul> <li>Susquehanna lowers Genesco (<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a> <font color='red'>-8.3%</font>) to a <a href=\"https://www.streetinsider.com/Analyst+Comments/Susquehanna+Downgrades+Genesco+%28GCO%29+to+Neutral%3B+Sees+Intensifying+Promotional+Activity/13240960.html\" target=\"_blank\">Neutral rating</a> from Positive due to the higher level of promotional activity it sees in key categories.</li> <li>The firm's lowered price target of $29 on GCO&nbsp;is 8.1X the FY18 EPS estimate of $3.56 and 7.5X the FY19 EPS estimate of $3.86.</li> <li>Shares of Genesco are now down 59% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292077\" data-linked=\"Susquehanna sours on Genesco\" data-tweet=\"$GCO - Susquehanna sours on Genesco https://seekingalpha.com/news/3292077-susquehanna-sours-on-genesco?source=tweet\" data-url=\"https://seekingalpha.com/news/3292077-susquehanna-sours-on-genesco\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292076\" data-ts=\"1503927816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292076-fitbit-smartwatch-wireless-headphones-and-smart-scale-available-for-preorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit smartwatch, wireless headphones, and smart scale available for preorder</a></h4><ul><li>        Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) <a href=\"https://seekingalpha.com/pr/16924867-fitbit-launches-ionic-ultimate-health-fitness-smartwatch\" target=\"_blank\">announces</a> Ionic, the company&rsquo;s first smartwatch.</li><li>               Ionic includes standard smartwatch features like GPS tracking, heart rate tracking, water resistance up to 50 meters, and on-device workouts.&nbsp;</li><li>               The watch also includes a relative SpO2 sensor, which allows for deeper health tracking of conditions like sleep apnea.&nbsp;</li><li>               Ionic can conduct contactless payments and has app partners including Starbucks, Pandora, and AccuWeather.&nbsp;</li><li>               The $299.95 Ionic is available for preorder now through Fitbit.com and will reach stores in October. A special Adidas edition will arrive next year.&nbsp;</li><li>               Fitbit also announces the release of the <a href=\"https://seekingalpha.com/pr/16924877-fitbit-launches-fitbit-flyer-wireless-headphones-built-fitness\" target=\"_blank\">Fitbit Flyer</a> wireless headphones and the <a href=\"https://seekingalpha.com/pr/16924866-fitbit-introduces-aria-2-accurate-wi-fi-smart-scale\" target=\"_blank\">Aria 2 Wi-Fi Smart Scale</a>, both available today for preorder for $129.95 each. &nbsp;</li><li>Fitbit shares are&nbsp;<font color='green'>up 4.45%</font>. &nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289306-raymond-james-upcoming-watch-release-critical-fitbit-profits\" target=\"_blank\">Raymond James: Upcoming watch release critical to Fitbit profits</a> (Aug. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292076\" data-linked=\"Fitbit smartwatch, wireless headphones, and smart scale available for preorder\" data-tweet=\"$FIT - Fitbit smartwatch, wireless headphones, and smart scale available for preorder https://seekingalpha.com/news/3292076-fitbit-smartwatch-wireless-headphones-and-smart-scale-available-for-preorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3292076-fitbit-smartwatch-wireless-headphones-and-smart-scale-available-for-preorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292072\" data-ts=\"1503926983\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATCEY\" target=\"_blank\">ATCEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292072-altice-to-buy-back-up-to-1b-in-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Altice to buy back up to \u20ac1B in shares</a></h4><ul>   <li>Ambitious cable firm Altice (<a href='https://seekingalpha.com/symbol/ATCEY' title='ALTICE S A ADR'>OTCPK:ATCEY</a>) will buy back up to &euro;1B in shares in the coming year.</li>    <li>The company says it's continuing to evaluate using its excess cash for either shareholder returns or M&amp;A -- and after creating its U.S. spin-off by buying Suddenlink and Cablevision, it's been rumored to have its eye on a run at Charter (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) after failing in a pursuit of Time Warner Cable.</li>    <li>The buybacks will come in its A and B class shares that will be canceled or held in its treasury.</li>    <li>Altice USA (NYSE:<a href='https://seekingalpha.com/symbol/ATUS' title='Altice USA'>ATUS</a>) is <font color='green'>up 2.4%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3292072\" data-linked=\"Altice to buy back up to \u20ac1B in shares\" data-tweet=\"$ATCEY $ATCEY $CHTR - Altice to buy back up to \u20ac1B in shares https://seekingalpha.com/news/3292072-altice-to-buy-back-up-to-1b-in-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3292072-altice-to-buy-back-up-to-1b-in-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292070\" data-ts=\"1503926820\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRV\" target=\"_blank\">TRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292070-major-insurers-poised-for-hurricane-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Major insurers poised for hurricane losses</a></h4><ul> <li>Travelers (NYSE:<a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a>) is <font color='red'>down 3%</font> and Allstate (NYSE:<a href='https://seekingalpha.com/symbol/ALL' title='Allstate Corporation'>ALL</a>) is <font color='red'>2% lower</font> as estimates on the total insurance losses from Hurricane Harvey range to as high as $25B.</li><li>Keep an eye on Progressive (NYSE:<a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a>) and National General (NASDAQ:<a href='https://seekingalpha.com/symbol/NGHC' title='National General Holdings Corp'>NGHC</a>) as well.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291986-cost-hurricane-harvey-damages\" target=\"_blank\">Cost of Hurricane Harvey damages?</a> (Aug. 28)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3292070\" data-linked=\"Major insurers poised for hurricane losses\" data-tweet=\"$TRV $TRV $ALL - Major insurers poised for hurricane losses https://seekingalpha.com/news/3292070-major-insurers-poised-for-hurricane-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3292070-major-insurers-poised-for-hurricane-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292069\" data-ts=\"1503926753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANTH\" target=\"_blank\">ANTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292069-antheras-blisibimod-shows-long-term-treatment-benefit-in-mid-stage-study-in-iga-nephropathy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anthera&#39;s blisibimod shows long-term treatment benefit in mid-stage study in IgA nephropathy; shares ahead 12% premarket</a></h4><ul><li>Thinly traded nano cap Anthera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a>) in up&nbsp;<font color='green'>12%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16924794-anthera-announces-top-line-final-data-extension-period-phase-2-bright-sc-study-blisibimod\" target=\"_blank\">announcement </a>of positive results from the extension period of a Phase 2 clinical trial, BRIGHT-SC, assessing Orphan Drug-tagged blisibimod in 58 patients with IgA nephropathy.</li><li>Throughout the treatment period and up to one year post-treatment, patients receiving blisibimod experienced stable disease as measured by proteinuria (protein in the urine). In addition, patients showed a trend toward preservation of renal function as measured by individual rates of change in estimate glomerular filtration rate.</li><li><a href=\"http://www.anthera.com/pipeline/science/a-623-blisibimod.html\" target=\"_blank\">Blisibimod&nbsp;</a>is a selective peptibody antagonist of the&nbsp;<a href=\"https://en.wikipedia.org/wiki/B-cell_activating_factor\" target=\"_blank\">B-cell activating factor</a>&nbsp;&#40;BAFF&#41;&nbsp;cytokine, a member of the tumor necrosis family that is critical to the development, maintenance and survival of B-cells. It binds to BAFF and inhibits the interaction of BAFF with its receptors thereby reducing the number of B-cells and mitigating the immune response.</li><li>The company plans to advance blisibimod into Phase 3 development.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292069\" data-linked=\"Anthera&#39;s blisibimod shows long-term treatment benefit in mid-stage study in IgA nephropathy; shares ahead 12% premarket\" data-tweet=\"$ANTH - Anthera&#39;s blisibimod shows long-term treatment benefit in mid-stage study in IgA nephropathy; shares ahead 12% premarket https://seekingalpha.com/news/3292069-antheras-blisibimod-shows-long-term-treatment-benefit-in-mid-stage-study-in-iga-nephropathy?source=tweet\" data-url=\"https://seekingalpha.com/news/3292069-antheras-blisibimod-shows-long-term-treatment-benefit-in-mid-stage-study-in-iga-nephropathy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292071\" data-ts=\"1503926720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292071-premarket-gainers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:10 am</a></h4><ul><li>&nbsp;<a href='https://seekingalpha.com/symbol/MXPT' title='MaxPoint Interactive'>MXPT</a> <font color='green'>+149%</font> on <a href=\"https://seekingalpha.com/news/3292020-valassis-acquire-maxpoint-interactive-13_86-per-share-cash\" target=\"_blank\">acquisition</a> by Valassis.</li><li><a href='https://seekingalpha.com/symbol/FSNN' title='Fusion Connect, Inc.'>FSNN</a> <font color='green'>+124%</font>.</li><li><a href='https://seekingalpha.com/symbol/IXYS' title='IXYS Corporation'>IXYS</a> <font color='green'>+41%</font> on <a href=\"https://seekingalpha.com/news/3291988-littelfuse-acquire-ixys-corporation\" target=\"_blank\">acquisition</a> by Littelfuse.</li><li><a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a> <font color='green'>+29%</font> on <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11b-cash-kite-16-percent-premarket\" target=\"_blank\">acquisition</a> by Gilead.</li><li><a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='green'>+20%</font> on sentiment of <a href=\"https://seekingalpha.com/news/3292009-gilead-kite-deal-stokes-buying-juno-therapeutics-8-percent-premarket\" target=\"_blank\">Gilead-Kite</a> deal.</li><li><a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a> <font color='green'>+18%</font> on conditional FDA approval of <a href=\"https://seekingalpha.com/pr/16924693-second-sight-receives-conditional-fda-approval-begin-first-orion-human-clinical-study\" target=\"_blank\">Orion Human</a> clinical study.</li><li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='green'>+16%</font> on positive <a href=\"https://seekingalpha.com/news/3292069-antheras-blisibimod-shows-long-term-treatment-benefit-mid-stage-study-iga-nephropathy-shares\" target=\"_blank\">Phase 2</a> results.</li></ul> &nbsp;<div class=\"tiny-share-widget\" data-id=\"3292071\" data-linked=\"Premarket Gainers as of 9:10 am\" data-tweet=\"$MXPT $FSNN $IXYS - Premarket Gainers as of 9:10 am https://seekingalpha.com/news/3292071-premarket-gainers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3292071-premarket-gainers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292066\" data-ts=\"1503926269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292066-amd-and-baidu-announce-data-center-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD and Baidu announce data center collaboration</a></h4><ul><li>        Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) and Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) <a href=\"https://globenewswire.com/news-release/2017/08/28/1101029/0/en/AMD-and-Baidu-Join-Forces-to-Advance-GPU-Computing-in-the-Datacenter-with-Radeon-Instinct-MI-Series.html\" target=\"_blank\">announce</a> a collaboration to use AMD Radeon Instinct GPUs in Baidu&rsquo;s data centers.</li><li>                  &ldquo;We are delighted to work with AMD to introduce AMD Radeon Instinct products into our datacenter and AI program, to build a more flexible and powerful computing platform that empowers AI products and accelerates the development of the global industry,\" says Liu Cao, senior director of Baidu&rsquo;s System Technologies Department.    </li><li>               AMD shares are&nbsp;<font color='green'>up 1.13%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>        Baidu shares are&nbsp;<font color='green'>up 0.61%</font>&nbsp;premarket.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291779-gpu-roundup-amd-low-supply-nvidia-delays-ship-date\" target=\"_blank\">GPU roundup: AMD low on supply, Nvidia delays ship date</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292066\" data-linked=\"AMD and Baidu announce data center collaboration\" data-tweet=\"$AMD $AMD $BIDU - AMD and Baidu announce data center collaboration https://seekingalpha.com/news/3292066-amd-and-baidu-announce-data-center-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3292066-amd-and-baidu-announce-data-center-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>77&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292063\" data-ts=\"1503925661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292063-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292063\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$RTNB $ABIL - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3292063-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3292063-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292062\" data-ts=\"1503925651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONVO\" target=\"_blank\">ONVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292062-organovos-murphy-resigns-from-chairmans-role-shares-slip-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Organovo&#39;s Murphy resigns from Chairman&#39;s role; shares slip 3% premarket</a></h4><ul><li>Keith Murphy, Chairman of Organovo (NASDAQ:<a href='https://seekingalpha.com/symbol/ONVO' title='Organovo Holdings, Inc.'>ONVO</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1497253/000156459017018094/onvo-8k_20170828.htm\" target=\"_blank\">resigned </a>in August 24 in order to avoid a conflict of interest with his new company which, he says, may be a potential customer of Organovo. He stepped down from his CEO role in April.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;premarket but only on 600 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292062\" data-linked=\"Organovo&#39;s Murphy resigns from Chairman&#39;s role; shares slip 3% premarket\" data-tweet=\"$ONVO - Organovo&#39;s Murphy resigns from Chairman&#39;s role; shares slip 3% premarket https://seekingalpha.com/news/3292062-organovos-murphy-resigns-from-chairmans-role-shares-slip-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292062-organovos-murphy-resigns-from-chairmans-role-shares-slip-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292057\" data-ts=\"1503924892\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292057-ziopharm-up-in-wake-of-gilead-kite-deal-shares-ahead-9-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm up in wake of Gilead-Kite deal; shares ahead 9% premarket</a></h4><ul><li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on light volume as the buying in CAR-T developers ripples out from Gilead's $11.9B takeout of Kite Pharma.</li><li>ZIOPHARM's lead candidate is a gene therapy for brain cancer. Its CAR-T candidates are all early-stage.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11b-cash-kite-16-percent-premarket\" target=\"_blank\">Gilead takes out Kite Pharma for $11B in cash; Kite up 16% premarket</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292057\" data-linked=\"Ziopharm up in wake of Gilead-Kite deal; shares ahead 9% premarket\" data-tweet=\"$ZIOP - Ziopharm up in wake of Gilead-Kite deal; shares ahead 9% premarket https://seekingalpha.com/news/3292057-ziopharm-up-in-wake-of-gilead-kite-deal-shares-ahead-9-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292057-ziopharm-up-in-wake-of-gilead-kite-deal-shares-ahead-9-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292050\" data-ts=\"1503924234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292050-bellicum-up-9-premarket-on-gilead-kite-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum up 9% premarket on Gilead-Kite deal</a></h4><ul><li>Bellicum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals'>BLCM</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on modestly higher volume as the buying ripples out to CAR-T developers after Gilead's announced $11.9B takeover of Kite Pharma.</li><li>The company's approach to CAR-Ts involves a breaking mechanism, or safety switch, designed to control cytokine release syndrome, a common problem with the therapies. Its lead candidate is Phase 1/2-stage BPX-501.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11b-cash-kite-16-percent-premarket\" target=\"_blank\">Gilead takes out Kite Pharma for $11B in cash; Kite up 16% premarket</a> (Aug. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292050\" data-linked=\"Bellicum up 9% premarket on Gilead-Kite deal\" data-tweet=\"$BLCM - Bellicum up 9% premarket on Gilead-Kite deal https://seekingalpha.com/news/3292050-bellicum-up-9-premarket-on-gilead-kite-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3292050-bellicum-up-9-premarket-on-gilead-kite-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292028\" data-ts=\"1503922557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIFE\" target=\"_blank\">LIFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292028-atyr-pharma-announces-45m-equity-financing-shares-ahead-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">aTyr Pharma announces $45M equity financing; shares ahead 6% premarket</a></h4><ul> <li>aTyr Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/LIFE' title='aTyr Pharma'>LIFE</a>) <a href=\"https://seekingalpha.com/pr/16924636-atyr-pharma-announces-45-million-equity-financing\" target=\"_blank\">announces</a> that it has entered into a definitive securities purchase agreement with certain institutional and other investors including members of the Company&rsquo;s Board of Directors. Gross proceeds are expected to be ~$45.8M.</li>   <li>Investors have agreed to purchase 5.9M shares of common stock at $2.65 per share. Viking Global Investors, one of the investors will purchase 2.3M shares of non-voting Class X Preferred Stock at $13.25 per share, each of which is convertible into 5 shares of common stock upon certain conditions. Each common share, and on an as-converted basis for the preferred stock, will be issued with a warrant to purchase 0.375 additional shares of aTyr&rsquo;s common stock at an exercise price of&nbsp;$4.64, representing a 75% premium to the purchase price of common stock, with an expiration date of December 31, 2019.</li>  <li>Net proceeds from the transaction will be used to advance its pipeline programs and for general corporate purposes.</li><li>Closing date is August 31.</li><li>Shares are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3292028\" data-linked=\"aTyr Pharma announces $45M equity financing; shares ahead 6% premarket\" data-tweet=\"$LIFE - aTyr Pharma announces $45M equity financing; shares ahead 6% premarket https://seekingalpha.com/news/3292028-atyr-pharma-announces-45m-equity-financing-shares-ahead-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292028-atyr-pharma-announces-45m-equity-financing-shares-ahead-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292027\" data-ts=\"1503921597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292027-gilead-kite-marriage-stokes-buying-in-cellectis-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead-Kite marriage stokes buying in Cellectis, up 8% premarket</a></h4><ul><li>Gilead's $11.9B takeout of Kite Pharma has stimulated buying in fellow CAR-T developer Cellectis (NASDAQ:<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>), up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li><li>The company's approach is \"off-the-shelf\" allogeneic products that it says overcomes the limitations of autologous therapies.</li><li>Pfizer is co-developing CAR-T candidate UCART19 with Servier, who acquired global rights from Cellectis in November 2015.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291992-gilead-takes-kite-pharma-11b-cash-kite-16-percent-premarket\" target=\"_blank\">Gilead takes out Kite Pharma for $11B in cash; Kite up 16% premarket</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3249858-fda-oks-pfizers-ind-car-t-candidate-ucart19\" target=\"_blank\">FDA OKs Pfizer's IND for CAR T candidate UCART19</a> (March 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292027\" data-linked=\"Gilead-Kite marriage stokes buying in Cellectis, up 8% premarket\" data-tweet=\"$CLLS - Gilead-Kite marriage stokes buying in Cellectis, up 8% premarket https://seekingalpha.com/news/3292027-gilead-kite-marriage-stokes-buying-in-cellectis-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292027-gilead-kite-marriage-stokes-buying-in-cellectis-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292016\" data-ts=\"1503920029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292016-fda-oks-expanded-use-of-astrazenecas-breast-cancer-med-faslodex-shares-ahead-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs expanded use of AstraZeneca&#39;s breast cancer med Faslodex; shares ahead 1% premarket</a></h4><ul><li>AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) is up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-us-fda-approval-as-monotherapy-for-expanded-use-in-breast-cancer.html\" target=\"_blank\">announcement </a>that the FDA has approved the use of <a href=\"https://www.faslodex.com/fulvestrant/metastatic-breast-cancer-treatment.html?source=FAS_C_C_69&amp;umedium=CPC&amp;uadpub=Google&amp;ucampaign=Faslodex_Branded_-_General&amp;ucreative=Faslodex_General&amp;uplace=faslodex&amp;cmpid=1\" target=\"_blank\">Faslodex </a>(fulvestrant) in postmenopausal women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have not received previous endocrine therapy.</li><li>The data supporting the new use was generated in the Phase 3 FALCON study.</li><li>The European Commission approved the new use in July.</li><li>Faslodex was previously approved in the U.S. for HR+ breast cancer following endocrine therapy and HR+/HER2- breast cancer, in combination with Pfizer's IBRANCE (palbociclib), that has progressed after endocrine therapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3292016\" data-linked=\"FDA OKs expanded use of AstraZeneca&#39;s breast cancer med Faslodex; shares ahead 1% premarket\" data-tweet=\"$AZN - FDA OKs expanded use of AstraZeneca&#39;s breast cancer med Faslodex; shares ahead 1% premarket https://seekingalpha.com/news/3292016-fda-oks-expanded-use-of-astrazenecas-breast-cancer-med-faslodex-shares-ahead-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292016-fda-oks-expanded-use-of-astrazenecas-breast-cancer-med-faslodex-shares-ahead-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292014\" data-ts=\"1503919841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UN\" target=\"_blank\">UN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292014-bernstein-sees-estee-lauder-strategic-for-unilever\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein sees Estee Lauder as strategic for Unilever</a></h4><ul> <li>Bernstein calls out Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>) as the favorite to snap up Estee Lauder (NYSE:<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a>) if a sales process is considered. The cosmetics company is seen as a strong strategic fit for Unilever.</li> <li>The firm thinks Estee Lauder could land an offer of $144 per share to value its at $53B.</li> <li>Source: Bloomberg</li> <li>Shares of Estee Lauder are <font color='green'>up 2.68%</font> in premarket action to $109.35 (all-time high territory) .</li><li>Previously: <a href=\"https://seekingalpha.com/news/3291766-takeover-rumors-lift-estee-lauder\" target=\"_blank\">Takeover rumors lift Estee Lauder</a> (Aug. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292014\" data-linked=\"Bernstein sees Estee Lauder as strategic for Unilever\" data-tweet=\"$UN $UN $UL - Bernstein sees Estee Lauder as strategic for Unilever https://seekingalpha.com/news/3292014-bernstein-sees-estee-lauder-strategic-for-unilever?source=tweet\" data-url=\"https://seekingalpha.com/news/3292014-bernstein-sees-estee-lauder-strategic-for-unilever\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3292009\" data-ts=\"1503919177\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3292009-gilead-kite-deal-stokes-buying-in-juno-therapeutics-up-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead - Kite deal stokes buying in Juno Therapeutics, up 8% premarket</a></h4><ul><li>CAR-T developer Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) is up&nbsp;<font color='green'>8%&nbsp;</font>premarket, albeit on only 1,100 shares, on the heels of Gilead's $11.9B takeout of Kite Pharma.</li><li>Juno sued Kite over its U.S. Patent No. 7,446,190 covering a construct for a CD-19-targeted CAR T cell treatment that employs a CD28 costimulatory domain claiming axicabtagene ciloleucel infringed. In December 2016, the USPTO agreed with Juno. The ruling is under appeal.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3231412-juno-prevails-car-t-patent-challenge-kite-pharma-seeks-judgement-kites-kte-c19-will-infringe\" target=\"_blank\">Juno prevails in CAR T patent challenge from Kite Pharma, seeks judgement that Kite's KTE-C19 will infringe when commercially produced</a> (Dec. 19, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3292009\" data-linked=\"Gilead - Kite deal stokes buying in Juno Therapeutics, up 8% premarket\" data-tweet=\"$JUNO - Gilead - Kite deal stokes buying in Juno Therapeutics, up 8% premarket https://seekingalpha.com/news/3292009-gilead-kite-deal-stokes-buying-in-juno-therapeutics-up-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3292009-gilead-kite-deal-stokes-buying-in-juno-therapeutics-up-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3291990\" data-ts=\"1503918314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3291990-aveos-tivozanib-okd-in-europe-shares-ahead-28-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO&#39;s tivozanib OK&#39;d in Europe; shares ahead 28% premarket</a></h4><ul><li>AVEO Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) is up&nbsp;<font color='green'>28%</font>&nbsp;premarket on average volume in response to the European Commission's <a href=\"https://seekingalpha.com/pr/16924563-aveo-oncology-announces-fotivda-tivozanib-approved-european-union-treatment-advanced-renal\" target=\"_blank\">approval </a>of FOTIVDA (tivozanib) for the first-line treatment of adult patients with advanced renal cell carcinoma &#40;RCC&#41; and adult RCC patients who are vascular endothelial growth factor receptor &#40;VEGFR&#41; and mTOR pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy.</li><li>EUSA Pharma owns the European rights under a December 2015 agreement.</li><li><a href=\"http://www.aveooncology.com/our-product-candidates/tivozanib/\" target=\"_blank\">Tivozanib&nbsp;</a>is an oral, once-daily, vascular endothelial growth factor &#40;VEGF&#41; tyrosine kinase inhibitor &#40;TKI&#41;. It is designed to optimize VEGF blockade while minimizing toxic side effects.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3227035-aveo-partner-eusa-pharma-advances-tivozanib-regulatory-application-europe\" target=\"_blank\">AVEO partner EUSA Pharma advances tivozanib regulatory application in Europe</a> (Nov. 28, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3291990\" data-linked=\"AVEO&#39;s tivozanib OK&#39;d in Europe; shares ahead 28% premarket\" data-tweet=\"$AVEO - AVEO&#39;s tivozanib OK&#39;d in Europe; shares ahead 28% premarket https://seekingalpha.com/news/3291990-aveos-tivozanib-okd-in-europe-shares-ahead-28-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3291990-aveos-tivozanib-okd-in-europe-shares-ahead-28-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3291992\" data-ts=\"1503917714\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GILD\" target=\"_blank\">GILD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3291992-gilead-takes-out-kite-pharma-for-11_9b-in-cash-kite-up-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gilead takes out Kite Pharma for $11.9B in cash; Kite up 16% premarket</a></h4><ul><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) has <a href=\"https://www.wsj.com/articles/gilead-to-buy-kite-pharma-for-roughly-11-billion-in-cash-1503916380\" target=\"_blank\">agreed to buy</a> Kite Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a>) for $180 per share or ~$11.9B in cash, a 29% premium over Friday's close of $139.10. The transaction should close in Q4.</li><li>Kite's CAR-T candidate axicabtagene ciloleucel for certain blood cancers is currently under regulatory review in the U.S. and Europe. The FDA's action date is November 29.</li><li>KITE is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3291992\" data-linked=\"Gilead takes out Kite Pharma for $11.9B in cash; Kite up 16% premarket\" data-tweet=\"$GILD $GILD $KITE - Gilead takes out Kite Pharma for $11.9B in cash; Kite up 16% premarket https://seekingalpha.com/news/3291992-gilead-takes-out-kite-pharma-for-11_9b-in-cash-kite-up-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3291992-gilead-takes-out-kite-pharma-for-11_9b-in-cash-kite-up-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>224&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3291989\" data-ts=\"1503916980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KITE\" target=\"_blank\">KITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3291989-kite-pharma-trading-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kite Pharma trading halted pending news</a></h4><ul><li>Nasdaq has <a href=\"http://www.nasdaqtrader.com/trader.aspx?id=tradehalts\" target=\"_blank\">suspended trading</a> in Kite Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/KITE' title='Kite Pharma'>KITE</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3291989\" data-linked=\"Kite Pharma trading halted pending news\" data-tweet=\"$KITE - Kite Pharma trading halted pending news https://seekingalpha.com/news/3291989-kite-pharma-trading-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3291989-kite-pharma-trading-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":60,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}